Korean J Schizophr Res.  2024 Apr;27(1):14-19. 10.16946/kjsr.2024.27.1.14.

Importance of Early Detection in Early Psychosis

• Joo SW

• KMID: 2554837
• DOI: http://doi.org/10.16946/kjsr.2024.27.1.14

Abstract

Early psychosis is the term coined in the hope that early intervention and treatment would benefit the long-term clinical outcomes of patients with psychosis. According to the clinical staging of psychosis, clinical high risk for psychosis and first-episode psychosis are allocated to early psychosis. Here, we described several clinical issues regarding the importance of early detection in early psychosis. As for clinical high risk for psychosis, we addressed the prevalence and clinical courses of clinical high risk for psychosis and whether early intervention services can lower the risk of psychosis onset in individuals with clinical high risk for psychosis. Regarding first-episode psychosis, we showed the prevalence of first-episode psychosis, the patterns, definitions, and clinical implications of the duration of untreated psychosis, and whether early intervention services can reduce the duration of untreated psychosis. With further research, we hope to achieve convincing evidence that early intervention can provide longterm benefits to patients with psychosis.

Keyword

Clinical high risk for psychosis; Early detection; Early intervention; Early psychosis; First-episode psychosis; 정신증 고위험군; 조기 개입; 조기 발견; 조기 정신증; 초발 정신증

Reference

1. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World psychiatry. 2008; 7:148.

2. Salazar de Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, et al. Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis. JAMA Psychiatry. 2021; 78:970–978.

3. Gottesman I, Erlenmeyer-Kimling L. Family and twin strategies as a head start in defining prodromes and endophenotypes for hypothetical early-interventions in schizophrenia. Schizophrenia research. 2001; 51:93–102.

4. Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res. 2020; 215:8–16.

5. Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10year follow-up study in the OPUS cohort. Schizophrenia Research. 2015; 168:84–91.

6. Peralta V, García de Jalón E, Moreno-Izco L, Peralta D, Janda L, Sánchez-Torres AM, et al. Long-Term Outcomes of First-Admission Psychosis: A Naturalistic 21-Year Follow-Up Study of Symptomatic, Functional and Personal Recovery and Their Baseline Predictors. Schizophr Bull. 2022; 48:631–642.

7. Fusar-Poli P, Cappucciati M, Rutigliano G, Heslin M, Stahl D, Brittenden Z, et al. Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. Schizophr Bull. 2016; 42:1395–1406.

8. Salazar de Pablo G, Woods SW, Drymonitou G, de Diego H, FusarPoli P. Prevalence of Individuals at Clinical High-Risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-Analysis. Brain Sci. 2021; 11.

9. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification. JAMA Psychiatry. 2016; 73:113–120.

10. Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P. Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res. 2013; 209:266–272.

11. Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, et al. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. JAMA Psychiatry. 2020; 77:755–765.

12. Solmi M, Soardo L, Kaur S, Azis M, Cabras A, Censori M, et al. Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment. Mol Psychiatry. 2023; 28:2291–2300.

13. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry. 2015; 172:249–258.

14. Fusar-Poli P, Díaz-Caneja CM, Patel R, Valmaggia L, Byrne M, Garety P, et al. Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatr Scand. 2016; 133:76–85.

15. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longerterm follow-ups. Schizophr Res. 2013; 149:56–62.

16. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of firstepisode psychosis: an overview. World Psychiatry. 2017; 16:251–265.

17. Bechdolf A, Müller H, Hellmich M, de Millas W, Falkai P, Gaebel W, et al. Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT). Schizophr Bull. 2023; 49:1055–1066.

18. Jongsma HE, Turner C, Kirkbride JB, Jones PB. International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. The Lancet Public Health. 2019; 4:e229–e244.

19. Simon GE, Coleman KJ, Yarborough BJH, Operskalski B, Stewart C, Hunkeler EM, et al. First Presentation With Psychotic Symptoms in a Population-Based Sample. Psychiatr Serv. 2017; 68:456–461.

20. Cho SJ, Kim J, Kang YJ, Lee SY, Seo HY, Park JE, et al. Annual Prevalence and Incidence of Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A National Health Insurance Data-Based Study. Psychiatry Investig. 2020; 17:61–70.

21. Jon DI, Lee SH, Kong JE. Clinical Correlates of Duration of Untreated Psychosis in Patients with Schizophrenia. J Korean Neuropsychiatr Assoc. 2004; 43:401–406.

22. Jung JC, Cho GH, Lee KH, Lee CR, Chung YC. Long-Term Outcomes of Patients with First-Episode Schizophrenia Spectrum Disorder and Effects of Duration of Untreated Psychosis on Them. Schizophrenia Clinics. 2005; 8:64–73.

23. Kim M, Kim JK, Jhon M, Kim JW, Lee JY, Kim JM, et al. Factors Affecting the Duration of Untreated Psychosis in CommunityDwelling Patients with Schizophrenia Spectrum Disorder. Korean Journal of Schizophrenia Research. 2020; 23:1–7.

24. Salazar de Pablo G, Aymerich C, Guinart D, Catalan A, Alameda L, Trotta G, et al. What is the duration of untreated psychosis worldwide? - A meta-analysis of pooled mean and median time and regional trends and other correlates across 369 studies. Psychol Med. 2024; 54:652–662.

25. Compton MT, Carter T, Bergner E, Franz L, Stewart T, Trotman H, et al. Defining, operationalizing and measuring the duration of untreated psychosis: advances, limitations and future directions. Early Intervention in Psychiatry. 2007; 1:236–250.

26. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001; 31:381–400.

27. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry. 2000; 157:808–815.

28. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry. 1993; 150:1349–1354.

29. Marchira CR, Supriyanto I, Good BJ. The association between duration of untreated psychosis in first psychotic episode patients and help seeking behaviors in Jogjakarta, Indonesia. Int J Cult Ment Health. 2016; 9:120–126.

30. Rizos EN, Michalopoulou PG, Siafakas N, Stefanis N, Douzenis A, Rontos I, et al. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology. 2010; 62:87–90.

31. Casey D, Brown L, Gajwani R, Islam Z, Jasani R, Parsons H, et al. Predictors of engagement in first-episode psychosis. Schizophr Res. 2016; 175:204–208.

32. Polari A, Lavoie S, Sarrasin P, Pellanda V, Cotton S, Conus P. Duration of untreated psychosis: a proposition regarding treatment definition. Early Interv Psychiatry. 2011; 5:301–308.

33. Jonas KG, Fochtmann LJ, Perlman G, Tian Y, Kane JM, Bromet EJ, et al. Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. Am J Psychiatry. 2020; 177:327–334.

34. Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry. 1986; 148:115–120.

35. Malla A, Norman R, Schmitz N, Manchanda R, BÉChard-Evans L, Takhar J, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological medicine. 2006; 36:649–658.

36. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research. 1992; 6:209–223.

37. Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, et al. Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS). Schizophrenia Research. 2005; 80:117–130.

38. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry. 1993; 150:1349–1354.

39. Drake RJ, Husain N, Marshall M, Lewis SW, Tomenson B, Chaudhry IB, et al. Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study. Lancet Psychiatry. 2020; 7:602–610.

40. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniformdisorders. British Journal of Psychiatry. 2004; 185:18–24.

41. Pelayo-Teran JM, Diaz FJ, Perez-Iglesias R, Suarez-Pinilla P, Tabares-Seisdedos R, de Leon J, et al. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med. 2014; 44:37–50.

42. O’Keeffe D, Kinsella A, Waddington JL, Clarke M. 20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis. Am J Psychiatry. 2022; 179:288–297.

43. Allott K, Fraguas D, Bartholomeusz CF, Diaz-Caneja CM, Wannan C, Parrish EM, et al. Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. Psychol Med. 2018; 48:1592–1607.

44. Bora E, Yalincetin B, Akdede BB, Alptekin K. Duration of untreated psychosis and neurocognition in first-episode psychosis: A meta-analysis. Schizophr Res. 2018; 193:3–10.

45. Howes OD, Whitehurst T, Shatalina E, Townsend L, Onwordi EC, Mak TLA, et al. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry. 2021; 20:75–95.

46. Oliver D, Davies C, Crossland G, Lim S, Gifford G, McGuire P, et al. Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. Schizophr Bull. 2018; 44:1362–1372.